Combifer vs NeotrofinCF-Anemia-Pregnant-Phase II
Phase 2
Suspended
- Conditions
- Anemia
- Registration Number
- RPCEC00000193
- Lead Sponsor
- ational Center of Bioproducts (BioCen)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Female
- Target Recruitment
- 390
Inclusion Criteria
1. Patients with pregnancy between 9 and 34 weeks of gestation.
2. Patients with figures hemoglobin less than 110 g / L.
3. Patients who have not received transfusions two weeks before the study.
4. Patients who do not have acute gastrointestinal disorders that mask treatment.
5. Patients who do not have severe anemia (hemoglobin less than 70 g / L).
6. Patients who gave their informed consent participation in the study.
Exclusion Criteria
1. Patients with diseases that cause diarrhea and vomiting.
2. Patients who received transfusions or specific treatment with iron during the two months prior to the study..
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Hemoglogin (g/L). Measurement time: at baseline, and every 8 weeks until childbirth.
- Secondary Outcome Measures
Name Time Method